Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Non-alcoholic Fatty Liver Disease SIG: NAFLD Progression: A Cross Talk with Microbiome

    Contains 3 Component(s) Recorded On: 11/08/2019

    Non-alcoholic Fatty Liver Disease SIG: NAFLD Progression: A Cross Talk with Microbiome presented at The Liver Meeting® 2019.

    At this symposium, experts share the latest advances in the research of the microbiome and its relationship with NAFLD. They will discuss the microbiome’s association with disease progression, fibrosis and hepatocellular carcinoma. Topics covered will include the “cross talk” between obesity, the microbiome and NAFLD in both animal models and humans.

    John Y.L. Chiang
    Vanessa Leone

  • Public Health/ Healthcare Delivery SIG: Population Screening for Liver Disease Worldwide

    Product not yet rated Contains 5 Component(s) Recorded On: 11/08/2019

    Public Health/ Healthcare Delivery SIG: Population Screening for Liver Disease Worldwide presented at The Liver Meeting® 2019.

    This timely program tackles the eternal question of how to best screen for liver disease in the general population. Speakers will take a global perspective to describe novel methods of screening, discuss high-risk patient populations and address issues of cost effectiveness and linkage to care.

    Maya Balakrishnan
    Fasiha Kanwal
    W. Ray Kim
    Andrew Yeoman

  • Hepatology Self-Assessment Program

    Contains 5 Component(s), Includes Credits

    The goal of Hepatology Self-Assessment Program (HSAP) is a quick way for physicians and health professionals who diagnose and treat patients with liver disease to guide their self-assessment of medical knowledge utilizing short quizzes based on topics from the ABIM Certification/ Maintenance of Certification Exam Blueprint in Transplant Hepatology. Practice with board-style questions can help to identify knowledge gaps and link learners to resources for additional self-study when these gaps are identified.

    The goal of Hepatology Self-Assessment Program (HSAP) is a quick way for physicians and health professionals who diagnose and treat patients with liver disease to guide their self-assessment of medical knowledge utilizing short quizzes based on topics from the ABIM Certification/ Maintenance of Certification Exam Blueprint in Transplant Hepatology. Practice with board-style questions can help to identify knowledge gaps and link learners to resources for additional self-study when these gaps are identified. 

    Release Date: November 8, 2019
    Expiration Date: November 7, 2022

    Upon completion of this activity, learners will be able to: 

    1) Identify knowledge gaps and target study to fill those gaps in preparation for the ABIM Certification/Maintenance of Certification Exam in Transplant Hepatology

    2) Identify resources available through the AASLD to facilitate self-assessment in preparation for MOC examinations in Transplant Hepatology

    Hepatologists   
    Gastroenterologists       
    Nurse Practitioners        
    Physician Assistants               
    Fellows/Trainees
    Primary Care Physicians
    Family Practice Physicians
    Internal Medicine Physicians
    Medical Students

    Satisfactory completion 

    Participants must pass a post-test with a score of 70% or higher and complete an evaluation to receive a certificate of completion. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your board requirement. All sessions must be viewed and all post-tests must be completed successfully to earn credits or points for this activity. Please note, no partial credits or points will be given.  

    Credits Offered Continuing Medical Education (CME): 2.5 AMA PRA Category 1 Credits™; Maintenance of Certification (ABIM MOC): 2.5 MOC Points

    Accreditation and Designation Statements

    Continuing Medical Education (CME):

    The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABIM Maintenance of Certification (ABIM MOC): 

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

    ABP Maintenance of Certification (ABP MOC):

    Successful completion of this CME activity, which includes participation in the activity and individual assessment of and feedback to the learner, enables the learner to earn up to 2 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

    Claiming CME Credits Physicians and other health care professionals seeking 2.5 AMA PRA Category 1 Credits™ for this enduring continuing medical education activity must complete an evaluation by November 7, 2022. 

    Claiming ABIM MOC Points Physicians seeking ABIM and or ABP MOC points must complete the CME and MOC evaluation by November 7, 2022. Requests for MOC after this date will not be honored. The MOC evaluation is included in the CME evaluation.

    MOC Points will be reported to the ABIM and ABP by the end of each month through November 2022 for individuals who successfully complete the MOC evaluation.

    DISCLOSURE OF CONFLICTS OF INTEREST

    AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosures are collected prior to the start of the educational activity. Any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.

    The organizers and faculty have reported the following disclosures:

    Question Writers, Editors and Reviewers 

    Oren K. Fix, MD, MSc, FAASLD
    Nothing to disclose

    Heather M. Patton, MD, FAASLD
    Nothing to disclose

    Helen S. Te, MD, FAASLD
    Research Grants: Conatus Pharmaceuticals, Abbvie, Gilead Sciences
    Advisory Board: Gilead Sciences,Intercept Pharmaceuticals

    Mark W. Russo, MD, MPH, FAASLD
    Commercial Speaker's Bureau: Gilead, Abbvie,Intercept, Salix

    Katie Duggan, BA
    Staff Liaison
    Nothing to disclose

    Maintenance of Certification Committee

    Mark W. Russo, MD, MPH, FAASLD
    Chair
    Commercial Speaker's Bureau: Gilead, Abbvie,Intercept, Salix

    Raymond T. Chung, MD, FAASLD
    Board Liaison
    Research Grants: Abbvie, Gilead Sciences, Boehringer Ingelheim

    Curtis K. Argo, MD, MS, FAASLD
    Member
    Nothing to disclose

    Steven K. Herrine, MD, FAASLD
    Member
    Research Grants: Gilead, BMS, Galectin, Interecept 
    Leadership in related society: Board, Committee, Journal: ABIM - Chair, Transplant Hepatology Test Committee

    Vandana Khungar, MD, MSc
    Member
    Nothing to disclose

    Ayman A. Koteish, MD, FAASLD
    Member
    Nothing to disclose

    Smruti R. Mohanty, MD, MS
    Member
    Advisory Board: Gilead science, Abbvie, Merck, Bristol Meyers Squib and Intercept
    Leadership in related society: Board, Committee, Journal: Publications Committee, American College of Gastroenterology (2009- Present) Education Committee Member, the Alliance for Academic Internal Medicine (AAIM) (July 2016-19) Editorial Board, World Journal of Gastroenterology (2007-Present) Editorial Board, Digestive Disease & Science (2009-Present) Editorial Board, World Journal of Hepatology

    Heather M. Patton, MD, FAASLD
    Member
    Nothing to disclose

    K. Gautham Reddy, MD, FAASLD
    Member
    Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Intercept, Gilead
    Research Grants: Merck Intercept Genfit
    Commercial Speaker's Bureau: Intercept
    Leadership in related society: Board, Committee, Journal: Member, Training Committee: American College of;

    Grace L. Su, MD, FAASLD
    Member
    Company: Management Position

    Ryan M. Taylor, MD
    Member
    Commercial Speaker's Bureau: Merck, Inc., Abbvie, Inc., Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., Bristol-Myers Squibb

    Helen S. Te, MD, FAASLD
    Member
    Research Grants: Conatus Pharmaceuticals, Abbvie, Gilead Sciences
    Advisory Board: Gilead Sciences,Intercept Pharmaceuticals

    Debra Guss, RN, NP-C, ACRN
    Associate
    Nothing to disclose

    Katie Duggan, BA
    Staff Liaison
    Nothing to disclose

  • Integrated Management of Alcohol-Related Liver Disease with Hepatologists and Addiction Specialists

    Product not yet rated Contains 2 Component(s) Recorded On: 10/24/2019

    Webinar hosted by the Alcohol-Related Liver Disease Special Interest Group on October 24, 2019.

    Patients with ALD and alcohol-related acute hepatitis (AH) have two diseases of liver failure with complications and of alcoholism or alcohol use disorder (AUD). Clearly, these patients need at least two or may be more specialists as basis for integrated and effective management and improved outcomes of this disorder. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Ashwani K. Singal

    Dr. Singal is an Associate Professor of Medicine at the University of South Dakota Sanford School of Medicine and Transplant Hepatologist at the Avera Transplant Institute. In addition, he also directs the hepatology elective course for the senior medical students at the Sanford Medical School and is Chief of Clinical Research Affairs at the Avera Transplant Institute. With clinical and translational research interests in alcoholic and non-alcoholic fatty liver diseases, renal injury in cirrhosis, and porphyria, Dr. Singal’s research has been funded by the American College of Gastroenterology, National Institute of Health, and pharmaceutical industry.

    He has over 160 original peer reviewed articles in national and international journals and book chapters. As an active executive member of the ACG practice parameters committee, Dr. Singal has developed practice guidelines for alcoholic liver disease and vascular disorders of the liver and currently involved in writing the guidelines on nutritional management of patients with cirrhosis. He also reviews research grants and scientific research abstracts for the AGA and AASLD. Dr. Singal is currently the Secretary and the Education subcommittee Chair of the Alcoholic Liver Disease Special Interest Group at AASLD.

    Lorenzo Leggio

    Lorenzo Leggio, MD, PhD, MSc is a physician-scientist who conducts clinical research on medication development and the role of neuroendocrine pathways in addictions. He is also an expert in the management and treatment of alcohol use disorder in patients with alcohol-related liver disease Dr. Leggio received his MD and PhD from the Catholic University of Rome and ‘Agostino Gemelli’ hospital (Italy), where he also completed residency and received Board Certification in Internal Medicine. He also received a masters in ‘Alcohol-related Diseases and Problems’ from the University of Florence. He was a visiting research associate, then postdoctoral research associate in Psychiatry and Human Behavior at Brown University in Providence, Rhode Island. Throughout his career, he has worked as a faculty member and principal investigator at Brown University and National Institutes of Health.

    Geetanjali Chander (Moderator)

    Geetanjali Chander, MD, MPH is an Associate Professor of Medicine and Epidemiology at Johns Hopkins University (JHU) School of Medicine. She is also an attending physician in the Bartlett Specialty Practice at Johns Hopkins Hospital where she practices HIV medicine among persons with alcohol, tobacco and other drug use. Her research focuses on the integration of evidence-based treatments for alcohol use into HIV, liver transplant and other clinical settings.

    She is a co-investigator on a NIAAA funded P50 focused on liver transplant among persons with acute alcohol related liver disease. For over 15 years she has been a co-investigator with the Johns Hopkins HIV Clinical Cohort. She is currently the PI of a U34 planning grant that uses community-based participatory research (CBPR) to implement alcohol interventions for women with and at risk of HIV. She is also the multi-PI of the administrative core of the NIAAA Alcohol Research Consortium in HIV (ARCH), which supports both an intervention arm and an epidemiology arm within the CFAR Network of Integrated Clinical Systems (CNICS), a multisite clinical cohort of persons with HIV.

    Dr. Chander is the Director of Research for the Brancati Center for the Advancement of Community Care at Johns Hopkins. The Brancati Center seeks to improve the health of communities by developing, evaluating and disseminating new models of healthcare that leverage the skills of a diverse range of health care providers.

  • The Diverse Presentation and Diagnosis of Liver Injury Due to Drugs or Herbal and Dietary Supplements

    Product not yet rated Contains 2 Component(s) Recorded On: 10/17/2019

    Webinar hosted by the Hepatotoxicity Special Interest Group on October 17, 2019.

    This webinar is targeted to AASLD Associate and Trainee members, as well as Junior Faculty. The goal is to provide an approach to the accurate diagnosis of Drug Induced Liver Injury (DILI), with special attention to considerations that may mask the diagnosis. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Paul (Skip) Hayashi

    Dr. Hayashi is currently Co-Chair of the Causality Committee for the Drug-Induced Liver Injury Network (DILIN) and Associate Professor at the University of North Carolina (UNC), Chapel Hill, NC. He is also Medical Director of Liver Transplantation at UNC.

    Prior to coming to UNC in 2006, he was Assistant Professor at Saint Louis University, St. Louis, MO, where he earned a Masters of Public Health. His training also includes a liver transplant fellowship at the University of Colorado, Denver, CO, and clinical research fellowship at the National Institutes of Health in the Liver Disease Section of NIDDK, Bethesda, MD. He earned his Medical Degree at the University of California, San Diego, CA and undergraduate degree in microbiology at UCLA in Los Angeles, CA.

    His ongoing research interests include epidemiology and diagnosis of drug-induced liver injury, and outcomes in liver transplantation and cirrhosis care.

    Andrew Stolz

    Dr. Stolz is the PI for the USC-UCLA Clinical Center for the past 12 years in the NIDDK Drug Induced Liver Injury Network (DILIN). In this capacity, Dr. Stolz and other investigators have characterized the clinical presentation of numerous pharmaceuticals or herbal and dietary supplemental induced liver injury as well as to identifying and exploring genetic variants associated with increased risk for liver injury. Dr. Stolz as co-chairperson of the Herbal and Dietary Supplement DILIN Subcommittee has a particular interest in body building supplement associated liver injury and genetic variants associated with their profound cholestatic liver injury.

    Adrian Reuben (Moderator)

    Dr. Reuben is Professor of Medicine Emeritus (January 2015) at the Medical University of South Carolina, in Charleston SC, where he directed the Liver Program that he created there in 1993. Dr. Reuben was born, raised and educated in London, UK, where he obtained his medical degree, completed his Residency and Fellowship in Gastroenterology (Guys Hospital, London) before completing a scholarship in the Liver Study Unit at Yale School of Medicine. He was appointed to the faculty at Yale (1981-1993) before moving to MUSC to establish a Liver Service and enhance the then fledgling Liver Transplant program.

    His continuing research interests focus on Acute Liver Failure, Coagulopathy in Liver Disease, Complications of Cirrhosis, and Drug Hepatotoxicity - in which he has co-authored many original articles.

    In addition to all aspects of clinical hepatology, he has considerable experience in liver transplantation, portal hypertension and hepatocellular carcinoma - about which he edited two issue in Clinics in Liver Disease. Until 2006 he also had a laboratory-based career that focused initially on biliary lipid secretion, and later on hepatic fibrogenesis. He has published over 100 peer-reviewed articles, editorials, case reports, book chapters and 44 essays on Hepatology history in the successful Landmarks in Hepatology series. Currently he is editing a new series of more than 50 essays on the History of Hepatology by renowned experts worldwide, to be published in the AASLD online journal Clinical Liver Disease (Editor: Nancy Reau, Rush Medical Center, Chicago IL).

    Reuben has presented original research papers at national and international meetings as well as teaching in postgraduate courses and workshops, and presenting invited lectures in the United States, Europe, the UK, and Asia. He served on several committees of the American Association for the Study of Liver Disease, including the Ethics Committee of which he was the Chair three years ago, and now he is the Chair-elect of the AASLD Hepatotoxicity Special Interest Group (SIG). Despite retirement from clinical practice, Adrian Reuben remains active in lecturing, collaborating in research projects, reviewing manuscripts, writing chapters and reviews as well as publishing original research articles. His interest in drug hepatotoxicity stems from his medical student days, when he obtained a bachelor degree in Pharmacology, and is exemplified by the publication of an original article in Hepatology, on Acute Liver Failure due to Drug-Induced Liver Injury, on behalf of the United States Acute Liver Failure Study Group (ALFSG), for which he was also the first author of an overview of 16 years’ experience in Acute Liver Failure.

    Finally, Reuben is to be the recipient of the 2019 AASLD Distinguished Service Award.

  • Systematic Screening for NAFLD-Related Advanced Fibrosis in Patient with Type 2 Diabetes, Where Do We Stand? WEBINAR

    Contains 2 Component(s) Recorded On: 10/09/2019

    Webinar hosted by the Nonalcoholic Fatty Liver Disease Special Interest Group on October 9, 2019.

    The systematic screening for NAFLD is currently not recommended by the AASLD practice guidelines although the presence of type 2 diabetes is a known risk factor for the progression of NAFLD towards NASH and advanced fibrosis. This webinar will discuss the pros and cons for the systematic screening of NAFLD-related advanced fibrosis in patient with type 2 diabetes. The point of view of the hepatologist and the diabetologist will be exposed in an interactive discussion. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Cyrielle Caussy

    Dr. Cyrielle Caussy is an associate professor of nutrition and an endocrinologist at Lyon 1 University and Lyon South Hospital in Lyon, France. During her medical training she graduated her PhD at Lyon 1 University studying the epigenetic regulation of plasma triglycerides concentration involving microRNAs at the CarMen laboratory (Cardio-Metabolism, Diabetes and Nutrition). Dr Caussy’ s main field of research interests are insulin-resistance and nonalcoholic fatty liver disease (NAFLD). She completed a 2-year advanced research training at the NAFLD Research Center, University of California at San Diego directed by Dr Rohit Loomba. She now has a specific interest in non-invasive biomarkers and pathophysiology of NAFLD, especially in high risk population such as type 2 diabetes and obese patients.

    Jörn Schattenberg

    Jörn M. Schattenberg, MD received his medical degree from the University of Mainz, Germany in 2002 after studying Medicine in Mainz, Germany and Tulane University, New Orleans (US). He completed his postdoctoral training at the Albert-Einstein College of Medicine, New York, where he focused on delineating signaling pathways involved in the pathophysiology of NASH. He trained in Medicine and Gastroenterology & Hepatology at the University Medical Center Mainz and is board-certified for Internal Medicine and GI. He leads the translational NAFLD Research Program at the University Medical Center Mainz and a basic science research laboratory focusing on clinical and experimental aspects of NAFLD/NASH, the development of therapeutic intervention and novel biomarkers. He participated in the development of the German guidelines on the treatment of NASH and acts as Editorial Board Member of HEPATOLOGY and the Journal of Hepatology.

    Veeral Ajmera (Moderator)

    Dr. Veeral Ajmera is Assistant Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of California, San Diego (UCSD). He conducts clinical and translational research in nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH).

    Dr. Ajmera is a member of the UCSD NAFLD Research Unit where he collaborates with a multidisciplinary team of experts on research in non-invasive biomarkers and patient factors associated with NAFLD severity and prognosis. He is a co-investigator for adult hepatology for the NIDDK-sponsored NASH Clinical Research Network and is a member of the American Association for the Study of Liver Diseases (AASLD). Dr. Ajmera also serves on the Education Committee of the AASLD. Dr. Ajmera has published widely in high impact gastroenterology and hepatology journals including GastroenterologyGut, HEPATOLOGY, Journal of HepatologyClinical Gastroenterology and HepatologyCellular and Molecular Gastroenterology and Hepatology and the American Journal of Gastroenterology. He also serves as the Medical Director of Liver Transplantation at UCSD and has a clinical emphasis on NAFLD and advanced liver disease.

  • Liquid Biopsy in Hepatocellular Carcinoma: Applications in Surveillance and Prediction of Treatment Response

    Product not yet rated Contains 2 Component(s) Recorded On: 10/02/2019

    Webinar hosted by the Hepatobiliary Neoplasia Special Interest Group on October 2, 2019.

    Liquid biopsy entails the analysis of tumor components released by cancer cells to biological fluids such as blood, saliva or cerebrospinal fluid. It has emerged as a promising source of novel biomarkers in the clinical management of patients with hepatocellular carcinoma. We will discuss the current developmental status of this technology and how it may change decision-making in patients with hepatocellular carcinoma. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Lewis R. Roberts

    Dr. Lewis R. Roberts is the Peter and Frances Georgeson Professor in Gastroenterology Cancer Research and a Consultant in the Division of Gastroenterology and Hepatology at the Mayo Clinic, where he is Director of the Hepatobiliary Neoplasia Clinic, Co-Chair of the Hepatobiliary Cancer Disease Group of Mayo Clinic Cancer Center, Co-Principal Investigator of the Mayo Specialized Program of Research Excellence (SPORE) in Hepatobiliary Cancers, Associate Director of Pre-Doctoral Programs in the Center for Clinical and Translational Sciences, and Director for Research at Mayo Clinic Alix School of Medicine. Dr. Roberts earned his medical degree from the University of Ghana Medical School, a PhD in Physiology and Biophysics from The University of Iowa, and completed postgraduate training in Internal Medicine, Gastroenterology and Hepatology, and Cancer Genetics at Mayo Clinic.

    Dr. Roberts clinical practice is focused on liver and biliary cancers. His research includes studies of the mechanisms of liver and biliary carcinogenesis; biomarkers to improve the diagnosis of liver, bile duct and pancreas cancers; and prevention, diagnosis and treatment of hepatitis and liver cancer. His research has been funded by NIH, The Robert Wood Johnson Foundation, the AGA Foundation, and The Cholangiocarcinoma Foundation. He has authored over 300 publications.

    Dr. Roberts currently serves as Deputy Editor of HEPATOLOGY and is on the Editorial Boards of Liver Cancer and Hepatic Oncology.

    Ju Dong Yang

    Dr. Yang is an academic faculty/staff physician in the Division of Digestive and Liver Diseases and Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center in Los Angeles, California, USA. He has contributed to clinical and translational research of liver cancer with over 50 scientific peer-reviewed original research articles. He has research interest in liquid biopsy and his scientific goal is to investigate an exciting area of individualized, precision medicine in the field of liver cancer. He serves as a member of Hepatobiliary Neoplasia Special Interest Group and an editorial board of HEPATOLOGY.

    John Kisiel

    My overall career goal is to reduce the burden of human suffering attributable to cancer through the early detection and treatment of pre-symptomatic disease. My primary research focus is the discovery and translational development of biomarkers for cancer detection by minimally invasive means. I lead a multidisciplinary team to integrate molecular markers, primarily methylated DNA, to noninvasively screen for cancers that are difficult to detect by currently available tools; with this effort, we hope to improve patient care and lower costs. I am a practicing gastroenterologist with clinical expertise in gastrointestinal neoplasia, inflammatory bowel disease and endoscopy.

    Our research team has an outstanding track record in the development of novel assay chemistry, specimen sampling and analyte preservation methodology in support of improved clinical or analytical sensitivity of tests to detect neoplasia. Our statistical core has developed novel methods for analysis of next-generation sequencing data and prediction methods for liquid biopsy results. Mayo Clinic is a leading clinical center of excellence with a high volume of cancer and at risk patients who are met by our outstanding clinical coordinator network. We have a close collaboration with the research and development laboratory at Exact Sciences (Madison Wisconsin USA) and are funded by the National Institutes of Health.

    Augusto Villanueva (Moderator)

    Augusto Villanueva is Assistant Professor in the Liver Cancer Program (Icahn School of Medicine at Mount Sinai, New York). He received his medical degree from the University of Santiago de Compostela (Spain), and he is board certified in Gastroenterology and Hepatology (Spain). In 2005, he joined the Division of Liver Diseases at Mount Sinai Hospital (New York) as a research fellow and was involved in different translational research projects focused on the molecular pathogenesis of hepatocellular carcinoma (HCC). In 2008, he obtained his PhD and received the Sheila Sherlock Fellowship from EASL to join the Liver Cancer Translational Research Laboratory of the BCLC Group, Barcelona (Spain). In 2010, he became the Scientific Manager of the HEPTROMIC consortium, a research initiative funded by the European Commission aimed at identifying genomic prognostic predictors and oncogenic drivers in HCC.

    In 2013, he joined the Institute of Liver Studies at King’s College (London), as a Senior Lecturer and Consultant Hepatologist where he served as co-leader of the HCC Clinic and Multidisciplinary Tumor Board. In 2014, he started his position at the Icahn School of Medicine at Mount Sinai with the goal of developing novel minimally invasive biomarkers using liquid biopsy and studying the impact of intratumor heterogeneity in HCC. He has more than 100 publications (10,000 citations, H-index 44) including articles in N Engl J MedNat GenetNat BiotechGastroenterology, HEPATOLOGY, J HepatolJ Clin InvestOncogene, etc. He wrote more than fifteen book chapters and edited a book on resistance to targeted therapies in HCC. He served as Associate Editor for J Hepatol (2014-2019) and Liver Cancer (2012-present).

  • Overview of Transplantation for Acute on Chronic Liver Failure - Webinar

    Contains 2 Component(s) Recorded On: 09/30/2019

    Webinar hosted by the Acute on Chronic Liver Failure Special Interest Group on September 30, 2019.

    In the first part of the webinar, we will provide an overview regarding the definitions of acute-on-chronic liver failure and the management of the cirrhotic patient with multi-organ system failure. In the second part, we will discuss several recent publications regarding wait list mortality and post-transplant outcomes for patients with severe acute-on-chronic liver failure. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Vinay Sundaram

    Dr. Vinay Sundaram is a transplant hepatologist at Cedars-Sinai Medical Center, where he serves as assistant medical director of liver transplantation and director of hepatology outcomes research. He has been a member of the AASLD since 2009. He is actively involved with numerous committees including the AASLD membership and mentorship committee, chair of the education subcommittee for the clinical practice special interest group.  In addition, he is on the membership and professional standards committee for UNOS. His research interests include end-stage liver disease, acute on chronic liver failure and post-transplant outcomes. He has over 100 published manuscripts and abstracts and is on the editorial board for Hepatology Communications. 

    Constantine J. Karvellas (Moderator)

    Dr. Constantine (Dean) Karvellas is an Associate Professor of Medicine (Critical Care Medicine and Gastroenterology/Hepatology) at the University of Alberta and an Adjunct Professor in the School of Public Health Sciences. He has been an attending intensivist in the E. Garner King General Systems Intensive Care Unit since 2009 and is involved with the Liver Transplant program as a Hepatologist. Dr. Karvellas is the only Canadian co-investigator in the NIH-funded United States Acute Liver Failure study group (US ALFSG). He is also a Vice Chair of the Society of Critical Care Medicine (SCCM) Liver management task force and serves as an Associate Editor for the Journal of Hepatology. Dr. Karvellas’ publications reflect his interests in acute liver failure (ALF), acute on chronic liver failure (ACLF), liver transplantation and extracorporeal liver support.

  • New Insights Into the Pathogenesis and Management of Cystic Fibrosis-Related Liver Disease

    Product not yet rated Contains 2 Component(s) Recorded On: 09/24/2019

    Webinar hosted by the Pediatric Liver Disorders Special Interest Group on September 24, 2019.

    Our understanding of liver disease pathogenesis and manifestations in cystic fibrosis is evolving, as ongoing research and clinical experience expands. This webinar will provide updates on current understanding of CLFD pathogenesis, on strategies for diagnosis and monitoring, and on management of CFLD complications. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    A. Jay Freeman

    Dr. Freeman is an Associate Professor of Pediatrics in the Gastroenterology, Hepatology and Nutrition Division at Emory University and Children’s Healthcare of Atlanta. He serves as the Director of Digestive Health for the Emory Children’s Cystic Fibrosis Program and Director of the Advanced Pancreatic Care Program at CHOA. He completed his pediatric residency at the University of Mississippi’s Batson’s Children’s Hospital and received his training in pediatric gastroenterology and hepatology at Emory University.

    As part of his clinical role Dr. Freeman oversees a dedicated CF clinic that serves patients with CF experiencing GI and liver disease including evaluation for liver transplantation. He is an active member of CFLD-NET with special interest in biomarkers and elastography as modalities to determine disease progression. Additionally, he is a member of the joint NASPGHAN-ESPGHAN committee tasked on defining and classifying CFLD, serves on the NASPGHAN Pancreas and CF committee, is the GI/Liver advisor on the CF Patient Registry-PHIs linkage project, and is a national primary investigator for the CF Foundation sponsored GALAXY Study which includes 26 sites across the United States. Most recently he was the lead author on the only manuscript that addresses the multi-disciplinary approach to pre- and post-transplant care for patients with CF undergoing liver transplantation.

    Daniel H. Leung (Moderator)

    Dr. Daniel H. Leung is an Associate Professor of Pediatrics within the Division of Gastroenterology, Hepatology, and Nutrition at Baylor College of Medicine and Director of Hepatology and Liver Transplant Medicine at Texas Children’s Hospital. He is devoted to the study and care of children with chronic fibroinflammatory liver diseases, with an emphasis on cystic fibrosis related liver disease and viral hepatitis. Dr. Leung was awarded a 3-year Developing Innovative Gastroenterology Specialty Training (DIGEST) grant by the CF Foundation in 2014 to further develop clinical and research expertise in the gastroenterological and liver care of people with CF.

    He currently serves as an investigator on the steering committee of the multi-center CF Liver Disease Network where he has focused on non-invasive measures of liver fibrosis (serum biomarkers and imaging) in children with CFLD. Dr. Leung’s academic interests include the etiopathogenesis of CFLD, novel therapies to reverse liver fibrosis or portal hypertension in CF and optimizing pre and post liver transplant outcomes of children with CF and liver disease.

    Michael R. Narkewicz (Moderator)

    Michael R. Narkewicz, MD, earned his medical degree from the University of Vermont in 1983. He completed his Pediatric Residency training at the University of Colorado School of Medicine in 1986. In 1989, he completed his Fellowship in Pediatric Gastroenterology and Nutrition at the University of Colorado School of Medicine, which also included two years of research as a Pediatric Scientist Training Program Fellow in Meudon-Bellevue, France.

    Dr. Narkewicz joined the faculty of the Department of Pediatrics at the University of Colorado School of Medicine and Children’s Hospital Colorado in 1989. He was appointed Professor of Pediatrics in 2003 and was awarded tenure in 2015. He was the Medical Director of the Pediatric Liver Center from 1998-2017 and Medical Director of the Liver Transplantation Program at The Children’s Hospital from 1998-2015. He served as the Director of the Fellowship Program in Pediatric Gastroenterology from 2005 to 2013 and as the Director of Clinical Services in Pediatric Gastroenterology from 2006-2011. He was the Associate Dean for Pediatric Clinical Affairs and Associate Medical Director for Pediatric Services for the University of Colorado School of Medicine and University of Colorado Medicine from 2011-2017. He was the Medical Director for Ambulatory Care at Children’s Hospital Colorado from 2011-2018. In 2017 he was named Executive for Strategic Provider Partnerships at Children’s Hospital Colorado.

    Dr. Narkewicz is nationally recognized for his expertise in pediatric hepatology and liver transplantation. His research interests include clinical studies in children with cystic fibrosis liver disease, pediatric chronic viral hepatitis biliary atresia, Fontan associated liver disease, hematologic and immunologic complications following pediatric liver transplantation, and clinical trials in acute liver failure and cystic fibrosis liver disease. Dr. Narkewicz is Principal Investigator of the Cystic Fibrosis Liver Disease Network leading 3 studies focused on identifying markers to predict the development of advanced CF liver disease including PUSH, ELASTIC and a proteomic study.

  • HCC Staging and Treatments

    Contains 2 Component(s) Recorded On: 09/10/2019

    Webinar hosted by the Hepatology Associates Interest Group on September 10, 2019.

    This webinar will cover Barcelona Clinic Liver Cancer (BCLC) staging in hepatocellular carcinoma. Attendees will also receive an overview of curative options of surgical resection, liver transplant, and ablative techniques and noncurative options of TACE, TARE, SBRT, and systemic chemotherapy. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Vicki Shah

    Vicki Shah PA-C, MMS received a Bachelor’s of Science in Biochemistry with minor in Mathematics from California State University, Long Beach. After completing neuroscience research at UCLA, she graduated from Midwestern University in Downers Grove, IL with a Masters in Medical Sciences and Physician Assistant Studies.

    She first started in underserved internal medicine and urgent care in Southern California. She became interested in gastroenterology after caring for her father who had esophageal cancer. She practiced in gastroenterology for five years at Carle Hospital with University of Illinois in Urbana, IL. Vicki joined Hepatology at Rush University in 2016 with a strong dedication to providing education as an instructor at the PA program, national lecturer for conferences, and APP medical advisory chair for American Liver Foundation. She is active in AASLD as a member of the Associates Committee and Associates SIG. Vicki is also on the editorial board for Clinical Liver Disease multimedia journal with AASLD and a reviewer for Fundamentals of Liver Disease.

    HoChong Gilles (Moderator)

    HoChong Gilles is a board-certified Nurse Practitioner and has been working in the hepatology field since 2001. She obtained a BS in Biology and Master’s in Nursing from Virginia Commonwealth University. She graduated with a Doctorate in Nursing Practice from the University of Virginia in 2018. Her research interests include portal hypertension and liver transplantation. She is the Clinical Program Manager for Hepatology and Liver Transplant at the McGuire Veterans Affairs Medical Center in Richmond, Virginia.

    Dr. Gilles is actively engaged in professional organizations including the American Association of the Study of Liver Diseases (AASLD). She was the immediate past Chair of the Hepatology Associates Committee is the Chair of the Hepatology Associates Special Interest Group. HoChong currently serves as the President of the Virginia Council of Nurse Practitioners.